DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer Pharmaceutical Investing
CEO Jeffery Bacha Discusses DelMar’s VOL-083 Clinical Trials and the Major Milestones Ahead Pharmaceutical Investing
DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market Pharmaceutical Investing
DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083 Pharmaceutical Investing
